Exhibit






	
																			
	 

	 
	1.  CONTRACT ID CODE
	PAGE OF PAGES

	AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT
	 
	1
	2

	2.  AMENDMENT/MODIFICATION NO. 
0001
	3.  EFFECTIVE DATE 
See Block 16C
	4.  REQUISITION/PURCHASE REQ. NO. 
OS235415
	5.  PROJECT NO. (If applicable)

	6.  ISSUED BY
	CODE
	HHS/OS/ASPR/BARDA
	7.  ADMINISTERED BY (If other than Item 6)
	CODE
	ASPR-BARDAO1

	US DEPT OF HEALTH & HUMAN SERVICES 
ASST SEC OF PREPAREDNESS & RESPONSE 
ACQ MANAGEMENT, CONTRACTS, & GRANTS 
O’NEILL HOUSE OFFICE BUILDING 
Washington DC 20515
	ASPR-BARDA 
330 Independence Ave, SW, Rm G644 
Washington DC 20201

	8.  NAME AND ADDRESS OF CONTRACTOR (No., street, county, State, and Zip Code)
	(x)
	9A.  AMENDMENT OF SOLICITATION NO.

	SIGA TECHNOLOGIES, INC. 1385150 
SIGA TECHNOLGIES, INC. 
31 East 62nd Street 
NEW YORK, NY 100658446
	 
	 

	 
	 

	 
	9B.  DATED (SEE ITEM 11)

	 
	 

	x
	10A.  MODIFICATION OF CONTRACT/ORDER NO. 
HHSO100201800019C

	 
	 

	 
	10B.  DATED (SEE ITEM 13)

	CODE  1385150
	FACILITY CODE
	 
	 
	09/10/2018

	11.  THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS

	 The above numbered solicitation is amended as set forth in Item 14.  The hour and date specified for receipt of Offers    is extended,   is not extended. Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended, by one of the following methods: 
(a) By completing Items 8 and 15, and returning _____ copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted; or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers.  FAILURE OF YOUR ACKNOWLEDGEMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER.  If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.

	12.  ACCOUNTING AND APPROPRIATION DATA (If required)   Net Increase:     $12,186,975.00

	2019.1990051.25505

	13.  THIS ITEM ONLY APPLIES TO MODIFICATION OF CONTRACTS/ORDERS. IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.

	CHECK ONE
	A.  THIS CHANGE ORDER IS ISSUED PURSUANT TO:  (Specify authority)  THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.

	 

	 
	B.  THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b).

	X
	C.  THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF: 
FAR 43.103(a) Bilateral Modification; FAR 17.207(c) (1) Exercise of Options with Avaliable Funds

	 
	D.  OTHER (Specify type of modification and authority

	E.  IMPORTANT:  Contractor     is not,  is required to sign this document and return       1      copies to the issuing office.

	14.  DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)

	Tax ID Number:  13-3864870 
DUNS Number:  932651516 
Procurement and Late-Stage Development of Smallpox Antiviral Drug(s) 
 
The purpose of this modification is to exercise Option CLIN0007 in the amount of $12,186,975.00 and change the COR information listed in Article G.2 as follows. 
Delivery:  12/31/2023 
Delivery Location Code:  HHS/OS/ASPR 
HHS/OS/ASPR
200 C St SW
WASHINGTON DC 20201 US 
Continued ...

	 

	Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.

	15A.  NAME AND TITLE OF SIGNER (Type or print) 
Dennis E Hurby, CSO
	16A.  NAME AND TITLE OF CONTRACTING OFFICER (Type or print)
Brooke Bernold

	 

	15B.  CONTRACTOR/OFFEROR 
/s/ Dennis E Hurby, CSO
	15C.  DATE SIGNED 
19 Feb 2019
	16b.  united states of america
	16c. date signed

	BY
	/s/ Brooke T. Bernold
	21 Feb 2019

	(Signature of person authorized to sign)
	 
	(Signature of Contracting Officer)
	 

	NSN 7540-01-152-8070
Previous Edition Unusable
	30-105
	STANDARD FORM 30 (Rev. 10-83)
Prescribed by GSA 
FAR (48 CFR) 53.243

	 




The purpose of this modification is to exercise Option CLIN0007 in the amount of $12,186,975.00 and change the COR information listed in Article G.2 as follows.
Article B.3. Option Prices
	
						
	CLIN
	Period of Performance
	Supplies/ Services
	Total Est. 
Cost
	Fixed Fee
	Total Cost Plus 
Fixed Fee ($)

	0007 (Option - Exercised)
	01/01/19 –
12/31/2023
	Phase IV post marketing commitments (nonparenteral (oral) formulation) including relabeling of approved drug in the SNS (this is an option that may or may not be exercised as required by the FDA)
	$11,497,147
	$689,828
	$12,186,975






Article G.2. Contracting Officer’s Representative (COR)
The following Contracting Officer’s Representative (COR) will represent the Government for the purpose of this contract:
David Simon
Contracting Officer’s Representative
Biomedical Advanced Research and Development Authority (BARDA)
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
David.Simon@hhs.gov 
(202) 260-1101